Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2169PDF: 1721HTML: 383 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2487PDF: 796HTML: 1738 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1402HTML: 475PDF: 834 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2149PDF: 1332HTML: 3505 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1994PDF: 772HTML: 702 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2837PDF: 1018HTML: 5526 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2296PDF: 1641HTML: 276 -
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS
2600PDF: 879HTML: 2125 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
2042PDF: 768HTML: 3117 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3067PDF: 918HTML: 2042 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2239PDF: 822HTML: 1636Figure 1: 194Table 1: 216 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2610PDF: 756HTML: 2312 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1265PDF: 1016HTML: 225 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4386PDF: 1773HTML: 1111 -
DEFERASIROX: OVER A DECADE OF EXPERIENCE IN THALASSEMIA
2955PDF: 1600HTML: 239 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3657PDF: 903HTML: 6722 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7660PDF: 2446HTML: 1740Table 1.: 214Table 2.: 224Table 3.: 208Table 4.: 209 -
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3303PDF: 950HTML: 2965 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1385PDF: 855HTML: 139 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2879PDF: 858HTML: 6533Untitled: 235Untitled: 198Untitled: 212Untitled: 224 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1821PDF: 992HTML: 147 -
ESCHERICHIA COLI: AN IMPORTANT PATHOGEN IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
1870PDF: 729HTML: 2118Untitled: 224Untitled: 157Untitled: 176Untitled: 160Untitled: 169Untitled: 183Untitled: 190 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1632PDF: 519HTML: 164 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1417PDF: 1326HTML: 101 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3971PDF: 762HTML: 1853 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1681PDF: 820HTML: 176 -
Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and granulocyte-colony stimulating factor with subsequent bridging to myeloablative allogeneic hematopoietic stem cell transplantation Treating relapsed/refractory acute myeloid leukemia with chidamide, fludarabine, cytarabine and G-CSF
1786PDF: 582HTML: 288
1 - 46 of 46 items







